Connect Biopharma Holdings Limited (NASDAQ:CNTB) Short Interest Update

Connect Biopharma Holdings Limited (NASDAQ:CNTB) was the recipient of a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 10,300 shares, a drop of 77.9% from the February 28th total of 46,700 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average trading volume of 20,500 shares, the short-interest ratio is presently 0.5 days.

Connect Biopharma Price Performance

CNTB traded up $0.03 during trading hours on Friday, reaching $0.79. 4,374 shares of the company’s stock traded hands, compared to its average volume of 50,103. The firm has a 50-day moving average price of $0.91 and a 200 day moving average price of $1.08. Connect Biopharma has a 52-week low of $0.76 and a 52-week high of $2.66.

Institutional Trading of Connect Biopharma

A number of large investors have recently made changes to their positions in CNTB. Catalina Capital Group LLC bought a new stake in Connect Biopharma during the 4th quarter valued at about $66,000. Callan Capital LLC grew its stake in Connect Biopharma by 91.3% in the 4th quarter. Callan Capital LLC now owns 80,000 shares of the company’s stock worth $110,000 after acquiring an additional 38,177 shares in the last quarter. Finally, Choreo LLC purchased a new position in shares of Connect Biopharma during the fourth quarter worth approximately $204,000. 58.72% of the stock is owned by hedge funds and other institutional investors.

Connect Biopharma Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.